Clinical trials: Haemostatic
Multiple Myeloma
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
The purpose of the study in Phase I is to select the recommended dose of bortezomib in combination with melphalan and prednisolone in Japanese participants.
- Trial name
- NCT00985959
- Testing
- JNJ-26866138 0.7 mg/m2, JNJ-26866138 1.0 mg/m2, JNJ-26866138 1.3 mg/m2
- Where
- 28 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma, Plasma Cell Leukemia
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe…
- Trial name
- NCT06045091
- Testing
- Human BCMA targeted CAR-NK cells injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections…
- Trial name
- NCT05650632
- Testing
- Etentamig (ABBV-383)
- Where
- 46 sites in United States, Canada and 5 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Hemostasis
Randomized Study of Accelerated Radial Arterial Hemostasis
Clinical randomized study to evaluate the effect of using a hydrophobically modified polysaccharide (hm-P) bandage
- Trial name
- GOLOW (NCT04593667)
- Testing
- hm-P bandage
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medcura Inc.
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Multiple Myeloma
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
- Trial name
- NCT01998971
- Testing
- Daratumumab, Velcade, Pomalidomide
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
Teclistamab pre-approval access in relapsed or refractory multiple myeloma.
- Trial name
- NCT05161598
- Testing
- Teclistamab
- Sponsor
- Janssen Research & Development, LLC
Hemophilia A
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.
- Trial name
- GENEr8-JPN (NCT06224907)
- Testing
- Valoctocogene roxaparvovec
- Where
- 4 sites in Japan
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BioMarin Pharmaceutical
Multiple Myeloma
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
- Trial name
- NCT00689507
- Testing
- LY2127399
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Applied Molecular Evolution
Multiple Myeloma
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in…
- Trial name
- NCT06484777
- Testing
- SHR-9539 for injection
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Relapsed Refractory Multiple Myeloma
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-002 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting…
- Trial name
- NCT04505813
- Testing
- NEXI-002 T Cells
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- NexImmune Inc.
Multiple Myeloma
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of…
- Trial name
- NCT00934154
- Testing
- Thalidomide, Melphalan+Prednisolone
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Cigdem Sahinbas YILMAZ
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- RACE (NCT00761722)
- Testing
- azacitidine
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Celgene
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma
- Trial name
- NCT01109069
- Testing
- PCI-32765
- Where
- 16 sites in United States
- Volunteers
- 199 people
- Sponsor
- Pharmacyclics LLC.
Severe Sepsis, Coagulopathy
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- NCT01598831
- Testing
- ART-123
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 816 people
- Sponsor
- Asahi Kasei Pharma America Corporation
Cancellous Bone Bleeding
A Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding
The purpose of this European study is to demonstrate the safety and performance of the SurgiClot® dressing in the treatment of cancellous bone bleeding.
- Trial name
- NCT02509208
- Testing
- SurgiClot haemostatic dressing
- Where
- 8 sites in Norway, United Kingdom
- Volunteers
- 30 people
- Sponsor
- St. Teresa Medical
Chronic Myeloproliferative Disorders, Infection
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT00002742
- Testing
- amphotericin B deoxycholate, nystatin
- Where
- 59 sites in United States
- Sponsor
- Aronex Pharmaceuticals